0.1500CAD+13.33%Mkt Cap: 3.02M $P/E: —7d ago
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap3.02M $
Enterprise Value3.20M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.32M $
Revenue/Share—
Last Price0.1500 CAD
Fiscal Year EndDec 2025
MR QuarterDec 2020
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.62
EV/Revenue—
P/S—
P/B-7.83
EPS (TTM)-0.41
EPS (Forward)—
52W Range
0.085013% of range0.5900
52W High0.5900 CAD
52W Low0.0850 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-6212.61%
ROA-204.71%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.24M $
CapEx (TTM)—
FCF Margin—
FCF Yield-64.52%
Net Debt9 $
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity18.58
Current Ratio0.55
Quick Ratio0.39
Book Value/Sh-0.0230 CAD
Cash/Share0.0000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 24, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.24.41M
Float21.49M
Insiders10.23%
Institutions0.00%
Short Interest
Short Ratio0.2d
Short % Out.0.02%
Shares Short75
Short (prev mo.)104.00K
Technical
SMA 500.1318 (+13.8%)
SMA 2000.1281 (+17.1%)
Beta-0.22
S&P 52W Chg18.16%
Avg Vol (30d)28.54K
Avg Vol (10d)31.72K
Technical Indicators
RSI (14)64.6
MACD0.0082
MACD Signal0.0025
MACD Hist.+0.0058
BB Upper0.1664 CAD
BB Middle0.1270 CAD
BB Lower0.0876 CAD
BB Width62.03%
ATR (14)0.0128 CAD
Vol Ratio (20d)0.23x